Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2 ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...

Receptor Tyrosine Kinase Treatment Market Driven by High Implementation of Targeted Therapy to Treat Cancer on Molecular Level; Global Market to Generate Over USD 102 Billion Revenue by 2030, Witnessing a CAGR of 7% over 2022-2030 New York, Nov. 11, 2021 (GLOBE NEWSWIRE) -- According to W.H.O. (World Health Organisation), cancer is the second leading cause of death in the world and accounted for nearly 10 million deaths in...

LB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors EAST SETAUKET, NY, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver,...